Jian Z Li

US Patent:

7482451, Jan 27, 2009

Filed:

Aug 18, 2003

Appl. No.:

10/643697

Inventors:

Mark E. Thompson - Anaheim Hills CA, US
Peter Djurovich - Long Beach CA, US
Jian Li - Los Angeles CA, US

Assignee:

The University of Southern California - Los Angeles CA

International Classification:

C07F 15/00
C07F 5/02
C07D 207/00
B01J 31/00

US Classification:

546 4, 546 11, 546 13, 548403, 502162, 502167, 502200

Abstract:

Emissive phosphorescent organometallic compounds that produce electroluminescence and organic light emitting devices employing such emissive phosphorescent organometallic compounds are provided. More specifically the present invention is directed to novel primarily non-emitting ligands which produce a blue shift in emitted light when associated with a cyclometallated ligand.

US Patent:

7741450, Jun 22, 2010

Filed:

Feb 8, 2007

Appl. No.:

11/672902

Inventors:

Philip M. Sass - Audubon PA, US
Nicholas C. Nicolaides - Boothwyn PA, US
Luigi Grasso - Bala Cynwyd PA, US
Jian Li - Fort Washington PA, US
Qimin Chao - Havertown PA, US
Eric Routhier - Glen Mills PA, US
Wolfgang Ebel - Philadelphia PA, US

Assignee:

Morphotek Inc. - Exton PA

International Classification:

C07K 16/24
C12N 5/12

US Classification:

53038823, 435326

Abstract:

Hybridoma lines that secrete human monoclonal antibodies with high binding specificity and biological activity, particularly neutralizing activity against granulocyte-macrophage colony stimulating factor, and methods of generating the hybridoma lines are provided. Target antigens and epitopes are also provided. The antibodies may be used in therapeutic methods, for example in the treatment of cancer, infectious disease, or autoimmune disease.

US Patent:

7893352, Feb 22, 2011

Filed:

Nov 22, 2005

Appl. No.:

11/286228

Inventors:

Mark E. Thompson - Anaheim Hills CA, US
Jian Li - Los Angeles CA, US
Stephen Forrest - Princeton NJ, US
Barry Rand - Princeton NJ, US

Assignee:

The Trustees of Princeton University - Princeton NJ
The University of Southern California - Los Angeles CA

International Classification:

H01L 31/00

US Classification:

136263

Abstract:

An organic photosensitive optoelectronic device, having an anode, a cathode, and an organic blocking layer between the anode and the cathode is described, wherein the blocking layer comprises a phenanthroline derivative, and at least partially blocks at least one of excitons, electrons, and holes.

US Patent:

8318168, Nov 27, 2012

Filed:

Apr 16, 2010

Appl. No.:

12/761464

Inventors:

Philip M. Sass - Audubon PA, US
Nicholas C. Nicolaides - Garnett Valley PA, US
Luigi Grasso - Bryn Mawr PA, US
Jian Li - Fort Washington PA, US
Qimin Chao - Havertown PA, US
Eric Routhier - Glen Mills PA, US
Wolfgang Ebel - Philadelphia PA, US

Assignee:

Morphotek, Inc. - Exton PA

International Classification:

A61K 39/395
C07K 16/22
C12P 21/08

US Classification:

4241411, 4241421, 4241451, 53038815, 53038823

Abstract:

Hybridoma lines that secrete human monoclonal antibodies with high binding specificity and biological activity, particularly neutralizing activity against granulocyte-macrophage colony stimulating factor, and methods of generating the hybridoma lines are provided. Target antigens and epitopes are also provided. The antibodies may be used in therapeutic methods, for example in the treatment of cancer, infectious disease, or autoimmune disease.

US Patent:

8439692, May 14, 2013

Filed:

Nov 1, 2011

Appl. No.:

13/286413

Inventors:

Dennis A. Oddsen - Northport NY, US
Jian H. Li - Bayside NY, US

Assignee:

Hubbell Incorporated - Shelton CT

International Classification:

H01R 4/66

US Classification:

439107

Abstract:

A triplex electrical receptacle has a flexible, compact arrangement of bus bars and phase, neutral and ground contacts associated with three outlets. Two outlets are nearest two corners of the body that share a common first side, and the third outlet is between them but closer to the opposite side of the body. A common neutral bus bar (with terminal) is connected to the neutral contacts of all three outlets. The phase bus bar (with terminal) is connected to the phase contacts of at least two of the outlets. One embodiment permanently connects the phase contact of the third outlet to the phase bus bar; another embodiment permanently isolates the third outlet, connecting its phase contact to a separate phase terminal; and an additional embodiment incorporates a separate phase terminal for the third outlet and an optionally severable connection between the third outlet and the first phase terminal.

US Patent:

8623364, Jan 7, 2014

Filed:

Oct 24, 2012

Appl. No.:

13/659165

Inventors:

Philip M. Sass - Audubon PA, US
Nicholas C. Nicolaides - Boothwyn PA, US
Luigi Grasso - Bala Cynwyd PA, US
Jian Li - Fort Washington PA, US
Qimin Chao - Havertown PA, US
Eric Routhier - Glen Mills PA, US
Wolfgang Ebel - Philadelphia PA, US

Assignee:

Morphotek, Inc. - Exton PA

International Classification:

A61K 39/395
C07K 16/00
C07K 16/22
C12P 21/08

US Classification:

4241411, 4241331, 4241391, 4241421, 4241451, 5303873, 5303879, 5303881, 53038815, 53038824

Abstract:

Hybridoma lines that secrete human monoclonal antibodies with high binding specificity and biological activity, particularly neutralizing activity against granulocyte-macrophage colony stimulating factor, and methods of generating the hybridoma lines are provided. Target antigens and epitopes are also provided. The antibodies may be used in therapeutic methods, for example in the treatment of cancer, infectious disease, or autoimmune disease.

US Patent:

20040018195, Jan 29, 2004

Filed:

Mar 26, 2003

Appl. No.:

10/397786

Inventors:

Don Griswold - North Wales PA, US
Jian Li - Secane PA, US
Li Li - Downingtown PA, US

International Classification:

C07H021/04
A61K039/395
C12N005/06
C07K016/26
G01N033/543

US Classification:

424/145100, 530/388250, 435/336000, 435/069100, 536/023530, 436/518000

Abstract:

The present invention relates to at least one novel diabetes related human Ig derived protein or specified portion or variant, including isolated nucleic acids that encode at least one diabetes related Ig derived protein or specified portion or variant, diabetes related Ig derived protein or specified portion or variants, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.

US Patent:

20050063944, Mar 24, 2005

Filed:

Sep 19, 2003

Appl. No.:

10/666490

Inventors:

Jian Li - Secane PA, US
Lamine Mbow - Malvern PA, US
Theresa Goletz - King of Prussia PA, US
David Peritt - Cynwyd PA, US

International Classification:

A61K038/19
A61K038/20

US Classification:

424085100, 424085200

Abstract:

The invention relates to the induction of responses relating to the maturation of dendritic cells, using IL-18 and IL-18 muteins, and compounds, compositions, methods of making and using thereof, including therapeutic methods and products.